Gut bacteria can interfere with the main treatment of Parkinson's disease

Published in Microbiology
Gut bacteria can interfere with the main treatment of Parkinson's disease

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Patients with Parkinson’s Disease are treated with levodopa, which is converted into the neurotransmitter dopamine in the brain. In a study that was published on 18 January in Nature Communications, we show that gut bacteria can metabolise levodopa into dopamine. As dopamine cannot cross the blood-brain barrier, this means the bacteria can compromise the availability of the medication, even in the presence of inhibitors that should prevent the conversion of levodopa. Check it at:

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Life Sciences > Biological Sciences > Microbiology

Related Collections

With collections, you can get published faster and increase your visibility.

Cancer and aging

This cross-journal Collection invites original research that explicitly explores the role of aging in cancer and vice versa, from the bench to the bedside.

Publishing Model: Hybrid

Deadline: Jul 31, 2024

Applied Sciences

This collection highlights research and commentary in applied science. The range of topics is large, spanning all scientific disciplines, with the unifying factor being the goal to turn scientific knowledge into positive benefits for society.

Publishing Model: Open Access

Deadline: Ongoing